EGFR and neoplasm: A second biopsy was gathered from a mCRC patient whose tumour carried genetic alterations in RNF43 and BRAF genes, and clinically responded and then relapsed to EGFR blockade with cetuximab in combination with the BRAF inhibitor encorafenib.